GlassScriptPhysician profile
Gavriel Fuzaylov
NPI 1154332310
$13,261.18
in general payments reported to CMS, 2019-2025
43 companies · $1,443 in 2025
The $1,443 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,424 · 2020: $1,167 · 2021: $1,709 · 2022: $3,224 · 2023: $2,016 · 2024: $2,279 · 2025: $1,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,737.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,471.37 | 2019-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $2,441.26 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,034.34 | 2019-2025 | |
| Glaxosmithkline, LLC. | $930.99 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $867.33 | 2019-2025 | Xifaxan, Trulance |
| Novo Nordisk INC | $625.23 | 2019-2024 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $505.12 | 2019-2024 | Jardiance, Synjardy |
| Regeneron Healthcare Solutions, INC. | $490.89 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $436.11 | 2019-2024 | Verquvo |
| Ardelyx, INC. | $266.52 | 2024-2025 | Ibsrela |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $239.84 | 2022-2024 | Caplyta |
| Amarin Pharma, INC. | $236.01 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $224.85 | 2019-2023 | Spravato |
| Ironwood Pharmaceuticals, INC | $218.62 | 2021-2024 | Linzess |
| Lilly USA, LLC | $196.20 | 2019-2025 | Mounjaro, Jardiance |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gavriel Fuzaylov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.